New guidelines for the use of the quadrivalent human papillomavirus vaccine, published by the American Academy of Pediatrics, recommend for the first time vaccinating adolescent boys as well as girls.
New guidelines for the use of the quadrivalent human papillomavirus vaccine (HPV4), published by the American Academy of Pediatrics (AAP), recommend for the first time vaccinating adolescent boys as well as girls.
The updated recommendations, published online February 27 in Pediatrics, follow a review of recommendations made by the Advisory Committee on Immunization Practices (ACIP) of the Centers for Disease Control and Prevention (CDC) in October 2011. That review was published in the December 2011 issue of the CDC’s Morbidity and Mortality Weekly Report (MMWR).
The evidence for HPV4 (Gardasil, Merck) vaccination of males was evaluated using grading of recommendations, assessment, development, and evaluation methods, according to the report.
“The American Academy of Pediatrics has reviewed updated data provided by the Advisory Committee on Immunization Practices on vaccine efficacy, safety, and cost-effectiveness as well as programmatic considerations and supports this recommendation. This revised statement updates recommendations for human papillomavirus (HPV) immunization of both males and females,” stated Michael T. Brady, MD, committee chairperson, and colleagues.
There are 2 HPV vaccines available in the United States, but the indications for each differ, and only HPV4 is approved for use in males.
HPV4 has been recommended since 2006 for use in females aged 9 through 26 years for prevention of outcomes of HPV types 6, 11, 16, and 18, such as vaginal, vulvar, and cervical pre-cancers and cancers and genital warts.
The vaccine was approved in 2009 for use in males to reduce their risk of acquiring genital warts, but it was not routinely recommended. Now, however, data suggest an increase in HPV-associated cancers in men, according to the MMWR report.
“In males, high-risk HPV types are responsible for a large proportion of cancers of the mouth and pharynx, which are increasing in recent years, and of anal and penile cancers,” according to the AAP’s statement. “Each year in the United States, approximately 15,000 cases of cancer in females and 7,000 cases of cancer in males are caused by HPV types 16 and 18.”
Vaccinating males would help to prevent their risk of genital warts and anal cancer, the authors said. And vaccination likely would provide an indirect benefit for females by reducing HPV 6, 11, 16, and 18 transmission and resulting infection, disease, and cancers through herd immunity, according to both the AAP and MMWR reports.
The rationale for routine HPV vaccination for boys aged 11 and 12 years is twofold, according to the AAP. Data suggest that antibody responses are highest for boys aged 9 through 15 years, and the vaccine is only effective if administered before the onset of sexual activity.
The AAP’s recommendations for males include the following:
Routine immunization for all boys ages 11 to 12 years with a 3-dose series of HPV4, administered intramuscularly at 0, 1 to 2, and 6 months. The vaccine can be given starting at age 9 years at the physician’s discretion.
All males aged 13 to 21 years not previously immunized or who have not completed the 3-dose series should receive HPV4 vaccine.
Men aged 22 to 26 years who have not been immunized previously or who have not completed the 3-dose series may receive HPV4 vaccine. The guidelines note that cost-efficacy models do not justify a stronger recommendation in this age group.
Special effort should be made to immunize men up to age 26 years who have sex with men and who have not been immunized previously or have not completed the 3-dose series.
The AAP offers implementation guidance documents regarding supply, payment, coding, and liability issues, which can be accessed from the organization’s website.
David Calabrese of OptumRx Talks Top Three Drugs in Pipeline, Industry Trends in Q2
July 1st 2020In this week's episode of Tuning Into The C-Suite podcast, MHE's Briana Contreras chatted with David Calabrese, R.Ph, MHP, who is senior vice president and chief pharmacy officer of pharmacy care services company, OptumRx. David is also a member of Managed Healthcare Executives’ Editorial Advisory Board. During the discussion, he shared the OptumRx Quarter 2 Drug Pipeline Insights Report of 2020. Some of the information shared includes the three notable drugs currently being reviewed or those that have been recently approved by the FDA. Also discussed were any interesting industry trends to watch for.
Listen
FDA Advisory Committee Votes Down Sotagliflozin in Type 1 Diabetes and CKD
November 1st 2024Committee members said there was uncertainty around sotagliflozin in patients with kidney disease. The FDA is currently reviewing the oral therapy as an adjunct to insulin to help control glycemic levels in adults with type 1 diabetes and chronic kidney disease. The agency’s goal date is Dec. 20, 2024.
Read More
ICER Gives Cell Therapy for Post-Transplant Complications High Rating
Published: October 31st 2024 | Updated: October 31st 2024ICER has given tabelecleucel a rating of A, indicating the T cell therapy for Epstein-Barr virus related post-transplant lymphoproliferative disease has a high certainty of substantial net health benefit and would be cost-effective if priced between $143,900 and $273,700.
Read More